FIELD: medicine.
SUBSTANCE: invention relates to a compound of general formula (I) wherein the Cy1 cycle is phenyl, cyclohexyl, pyridinyl, pyrazolyl, triazolyl, thienyl, tetrahydrofuranyl; Cy2 cycle is a pyridine ring, a pyrimidine ring, a pyrazolopyrimidine ring, an imidazopyridazine ring, an imidazopyridine ring, a pyrrolopyridine ring, an imidazopyrazine ring or a pyrazolopyridine ring; R1 represents a halogen; C1-6-alkyl group optionally substituted with 1 to 3 substituents selected from the group consisting of (i) halogen and (ii) hydroxy or C2-6-alkynyl group; phenyl optionally substituted with one or two R5 groups or indanyl; A 5-6 membered monocyclic heterocycle optionally substituted with one or two R5 groups or dihydrobenzofuran; -S(O)m1-R6; -SO2NR7R8; -OR14; R5 represents a halogen; cyano group; or C1-3-alkyl group optionally substituted with 1 to 3 substituents selected from the group consisting of (i) halogen, (ii) hydroxy groups and (iii) oxo groups; when there are two groups R5, the group R5 independently may be the same or different; R6, R7, R8, R14 or R20 respectively and independently represent (1) a hydrogen atom or (2) C1-6-alkyl group optionally substituted by (ii) a hydroxy group; R2 represents a halogen; C1-6-alkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group; C3-6-cycloalkyl group; C1-6-alkoxy group; -NR28R29; pyrrolidinyl, azetidinyl; or -O-(oxetanyl); R28 and R29 respectively and independently represent a hydrogen atom or C1-6-alkyl group optionally substituted by (ii) a hydroxy group; A1 and A2 respectively and are independently =CR3- or =N-; A3, A4, A5 and A6 respectively and are independently =CR4-; R3 and R4 respectively and independently represent a hydrogen atom; m1 is an integer from 0 to 2; p is an integer from 0 to 4; q is an integer from 0 to 2; r represents 0; provided that when p, q and r are respectively an integer of 2 or more, group R1, R2 and R3 respectively, and independently may be the same or different, or a pharmaceutically acceptable salt thereof. Invention also relates to a pharmaceutical composition having an inhibitory activity against Trk based on a compound of formula (I).
(I).
EFFECT: technical result consists in that new compounds have been obtained that can be used in medicine for the treatment of pain or cancer.
18 cl, 8 tbl, 23 ex
Title | Year | Author | Number |
---|---|---|---|
NOVEL HETEROCYCLES | 2009 |
|
RU2572616C2 |
HETEROCYCLIC COMPOUNDS AND METHODS OF APPLICATION | 2009 |
|
RU2525116C2 |
GLYCOLATOXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | 2018 |
|
RU2805308C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
NEW TETRAHYDROPYRIMIDINE CONNECTION OR ITS SALT | 2015 |
|
RU2636310C1 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
INHIBITING JAK COMPOUNDS BASED ON PYRAZOLOPYRIMIDINE AND METHODS | 2010 |
|
RU2675857C2 |
HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | 2018 |
|
RU2797822C2 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
Authors
Dates
2018-09-25—Published
2014-02-18—Filed